Therapeutics Inc.

therapeuticsinc.com

Therapeutics Inc. is a drug research and development company focusing on integration of clinical and regulatory strategies, trial design, product development, and marketplace analysis. The company’s services include clinical development project management, medical monitoring, and non-clinical development such as designing and managing pharmacology and toxicology programs. Therapeutics develops drugs and devices for acne, psoriasis, melasma, excess facial hair, injectable fillers, photoaging, and onychomycosis. The company was founded in 1997 and is headquartered in San Diego, California.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

APT THERAPEUTICS INC. ENTERS WORLDWIDE COLLABORATION, OPTION AND ASSET PURCHASE AGREEMENT FOR INVESTIGATION OF HUMAN APYRASE THERAPY

Pharmacy Choice | January 18, 2017

news image

By a News Reporter-Staff News Editor at Biotech Week APT Therapeutics, Inc., a privately-held biopharmaceutical company, announced a research collaboration, option and asset purchase agreement with AstraZeneca. APT Therapeutics has applied proprietary protein engineering strategies to develop APT102, an innovative human apyrase therapy for the treatment of thrombotic diseases. Uniquely different than current FDA-approved antithrombotic drugs that can increase bleeding risk, APT102 attenuated clo...

Read More

PRECISION THERAPEUTICS’ SUBSIDIARY, TO STUDY INNOVATIVE PERSONALIZED MEDICINE OPPORTUNITIES FOR CANCER PATIENTS

Precision Therapeutics Inc. | April 11, 2019

news image

PITTSBURGH, April 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its wholly-owned subsidiary, Helomics® Corporation (Helomics), which provides personalized medicine solutions and boutique CRO services for clients in the pharmaceutical, diagnostic, and biotechnology industries, and SpeciCare, an innovative Georgia-based company connecting cancer patients to new treatment options only available...

Read More

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

news image

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More

CIVICA RX PARTNERS WITH THERMO FISHER SCIENTIFIC TO DEVELOP AND MANUFACTURE DRUGS WITH A HISTORY OF DRUG SHORTAGES

Business Wire Press Releases | January 16, 2020

news image

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...

Read More
news image

APT THERAPEUTICS INC. ENTERS WORLDWIDE COLLABORATION, OPTION AND ASSET PURCHASE AGREEMENT FOR INVESTIGATION OF HUMAN APYRASE THERAPY

Pharmacy Choice | January 18, 2017

By a News Reporter-Staff News Editor at Biotech Week APT Therapeutics, Inc., a privately-held biopharmaceutical company, announced a research collaboration, option and asset purchase agreement with AstraZeneca. APT Therapeutics has applied proprietary protein engineering strategies to develop APT102, an innovative human apyrase therapy for the treatment of thrombotic diseases. Uniquely different than current FDA-approved antithrombotic drugs that can increase bleeding risk, APT102 attenuated clo...

Read More
news image

PRECISION THERAPEUTICS’ SUBSIDIARY, TO STUDY INNOVATIVE PERSONALIZED MEDICINE OPPORTUNITIES FOR CANCER PATIENTS

Precision Therapeutics Inc. | April 11, 2019

PITTSBURGH, April 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its wholly-owned subsidiary, Helomics® Corporation (Helomics), which provides personalized medicine solutions and boutique CRO services for clients in the pharmaceutical, diagnostic, and biotechnology industries, and SpeciCare, an innovative Georgia-based company connecting cancer patients to new treatment options only available...

Read More
news image

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More
news image

CIVICA RX PARTNERS WITH THERMO FISHER SCIENTIFIC TO DEVELOP AND MANUFACTURE DRUGS WITH A HISTORY OF DRUG SHORTAGES

Business Wire Press Releases | January 16, 2020

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us